您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > GDC-0032
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
GDC-0032
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
GDC-0032图片
包装与价格:
包装价格(元)
10mM (in 1mL DMSO)电议
5mg电议
10mg电议
25mg电议
100mg电议

产品介绍
GDC-0032 (GDC-0032) 是一种有效的 PI3K 抑制剂,靶向 PIK3CA 突变,对 PI3Kδ 的 Kis 分别为 0.12 nM、0.29 nM、0.97 nM 和 9.1 nM;PI3Kα;PI3K&#和PI3Kβ,分别。

Cell lines

MCF7-neo/HER2 cells

Preparation method

This compound is soluble in DMSO. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 ℃ for several months.

Reacting condition

2.5 nM

Applications

In MCF7-neo/HER2 cells, GDC-0032 inhibited cell proliferation with an IC50 value of 2.5 nM.

Animal models

MCF7-neo/Her2 xenograft model

Dosage form

1.4, 2.8, 5.8, 11.25 or 22.5 mg/kg; p.o.; q.d., for 20 days

Applications

GDC-0032 dose-dependently increased TGI and tumor regressions. In addition, GDC-0032 was well-tolerated with less than 10% body weight loss observed when compared with the vehicle group.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

产品描述

GDC-0032 is a novel and potent benzoxepin inhibitor of PI3Kα isoform with the Ki value of 0.29nM for PI3Kα[1].

GDC-0032 has been reported to potently inhibit PI3Kα and have the selectivity over other PI3Ks with the IC50 values of 0.29nM, 0.91nM and 0.97nM for PI3Kα, PI3Kβ and PI3Kγ, respectively. In addition, GDC-0032 has been revealed to suppress the proliferative cellular activity with the EC50 value of 25nM and 571nM in MCF7 cells and PC3 cells, respectively. The IC50 values of GDC-0032 inhibiting cell activity are 4nM and 31nM in MCF7 cells and PC3 cells, respectively. In vivo, GDC-0032 has shown the inhibition of growth in MCF7-neo/Her2 xenograft model grown in nude mice [1].

References:
[1] Ndubaku CO1, Heffron TP, Staben ST, Baumgardner M, Blaquiere N, Bradley E, Bull R, Do S, Dotson J, Dudley D, Edgar KA, Friedman LS, Goldsmith R, Heald RA, Kolesnikov A, Lee L, Lewis C, Nannini M, Nonomiya J, Pang J, Price S, Prior WW, Salphati L, Sideris S, Wallin JJ, Wang L, Wei B, Sampath D, Olivero AG. Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity. J Med Chem. 2013 Jun 13;56(11):4597-610.